FDA's First Step In Xenazine Review: Work Around Clinical Evidence Guidance

Shepherding the orphan Huntington’s chorea drug Xenazine through a three-year review, top-level FDA reviewers invoked the concept of "confirmatory evidence" to circumvent the agency’s preference for two randomized clinical trials to support new drug approval.